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ABSTRACT 
Background: Betaherpesviruses are established causes of morbidity and mortality in immune suppressed 
patient groups but they have been little studied in sub-Saharan Africa, the epicenter of the HIV pandemic. 
In this region, primary infections with human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6) 
are endemic in infancy, but the clinical impact of these infections among pediatric inpatient groups is 
poorly characterized and assumptive, based largely on data from Western populations. 
Methods:  We used Taqman PCR to screen sera from a group of 303 paediatric inpatients aged between 
3 weeks and 2 years of age, at the University Teaching Hospital, Lusaka, Zambia. We report the prevalence 
of DNAemia and viral loads within this patient group, and evaluate possible clinical associations/risk 
factors for betaherpesvirus infections in these hospitalized infants.  
Results: We detected betaherpesvirus DNAemia in 59.1% (179/303) of infants. HCMV was the most 
prevalent (41.3%), followed by HHV-6B (20.5%), HHV-7 (20.1%) and HHV-6A (0.3%). HIV infection (OR2.31, 
95%CI:1.37-3.9, p=0.002) being underweight (OR1.82, 95%CI:1.06-3.12, p=0.03) and an admission 
diagnosis of suspected meningitis (OR5.72, 95%CI1.07-30.5, p=0.041) were independently associated with 
an increased odds of HCMV DNAemia. Conversely, HHV-6B and HHV-7 DNAemia were not associated with 
HIV, underweight or admission diagnosis. Median HCMV viral load was moderately but significantly higher 
in HIV-infected children.  
Conclusions: Highly prevalent HCMV DNAemia was independently associated with HIV infection and being 
underweight across all age groups, and was also associated with meningitis, with previously under 
appreciated implications for the health and development of African children. 
KEYWORDS: Betaherpesvirus, HCMV, HHV-6, HHV-7, cytomegalovirus, malnutrition, underweight, HIV, 
Africa, infant  
INTRODUCTION 
The human betaherpesviruses (Human cytomegalovirus (HCMV), Human herpesvirus 6A (HHV-6A), 
Human herpesvirus 6B (HHV-6B) and Human herpesvirus 7 (HHV-7) are important causes of morbidity in 
infants and HCMV and HHV-6 are well-established causes of morbidity and mortality in immune-
compromised patients [1, 2], but they have been little studied in sub-Saharan Africa, the WHO region with 
the highest pediatric disease burden and also the epicenter of the HIV pandemic. Primary HCMV and HHV-
6 infections are endemic in African infants [3-5], establishing life-long latency with periodic reactivations 
or re-infections [1]. The great challenge in herpes virology is to differentiate active infections causing 
pathology from background sub-clinical viraemia. To this end, the latest quantitative molecular 
diagnostics are being used to establish clinically informative viral load cut-offs in different patient groups 
and within different compartments, which can inform on treatment [6-8]. The betaherpesviruses are 
highly cell-associated and within vulnerable patient groups detection of high HCMV and HHV-6 DNA loads 
in serum is indicative of active infections linked with poor outcomes [8, 9], but absence or low viral loads 
in serum does not rule out localized infection restricted to specific compartments [10].  
Recent prospective studies and careful review of some older but overlooked studies, has lead to a growing 
awareness of the importance of HCMV infections in high seroprevalence settings [11-13], as a major cause 
of mortality in HIV-infected children [14, 15] and as a cause of developmental delay [5] and hearing loss 
[16-18] in children through either congenital or early infant infections, with maternal HIV infection and 
lower CD4 count associated with higher prevalence of congenital infection [15, 19]. Human herpesvirus 
6A (HHV-6A), Human herpesvirus 6B (HHV-6B) and Human herpesvirus 7 (HHV-7)) have been less well 
studied in sub-Saharan Africa. HHV-6B primary infection (and to a lesser extent HHV-7), is the etiological 
agent of exanthema subitum, an endemic childhood illness characterized by fever, diarrhea and skin rash 
[20, 21], and is strongly associated with febrile seizures [22] including febrile status epilepticus (FSE) [23]. 
HHV-6A is rare rarely found in children in Europe, the U.S and Japan, but a recent study found HHV-6A to 
be endemic in healthy Zambian infants [3]. Elsewhere, HHV-6A is more common in immune-compromised 
adults, and recent animal model studies have suggested possible roles for HHV-6A in immune deficiency 
[24] and AIDS progression [25]. A study in U.S children also demonstrated an association between HHV-
6B and AIDS progression [26].  
In sub-Saharan Africa tertiary referral hospitals concentrate large numbers of seriously ill children from 
impoverished urban communities. At such centers drugs to control HIV, TB, Malaria and other common 
bacterial, fungal and parasite infections are broadly available, yet mortality rates remain high [27]. Rapid 
diagnostics and treatment for viral infections are broadly unavailable but HCMV is an important cause of 
respiratory disease in HIV-infected African children [8, 14, 28, 29] and HHV-6 and HHV-7 are possible 
causes of non-malarial CNS infections [30]. HCMV pneumonia can be treated successfully with intravenous 
Ganciclovir in both immunocompromised (HIV-infected South African infants with confirmed HCMV 
infection)[28, 29] and immunocompetent children [31]. There are generic anti-CMV drugs in the pipeline 
and anti-betaherpesvirus activity has been reported for several low cost alternatives such as artesunate 
[32, 33] and the immune stimulant ‘active hexose correlated compound’ (AHCC)[34]. Here we present 
data from a broad group of admitted infants at the University Teaching Hospital in Lusaka, Zambia, with 
the aim of determining prevalence of betaherpesvirus DNAemia and viral loads, and identifying possible 
clinical associations and risk factors. 
METHODS 
Ethics approval 
The study was approved by the Biomedical Research Ethics Committee of the University of Zambia School 
of Medicine (UNZABREC), Lusaka, Zambia. The mothers/guardians of all participants gave written 
informed consent. 
Study Design and Setting 
We conducted a retrospective observational study to determine the prevalence, viral loads and risk 
factors associated with betaherpesvirus DNAemia in admitted infants at the University Teaching Hospital, 
Lusaka, Zambia. We selected biobanked sera specimens from infants aged between 3 weeks and 2 years 
of age, admitted to the general paediatric inpatient wards, who had taken part in a TB diagnostic trial [35], 
and screened them for all four betaherpesviruses and measured viral loads. The degree to which the 
recruited children were representative of the broader inpatient population was evaluated by comparing 
key demographic data with that from general admission records. 
DNA Extraction & PCR Analysis 
Laboratory analysis was conducted in our dedicated 3-room molecular diagnostics laboratory. DNA from  
serum was extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) as previously described 
[4, 15]. Extraction controls were included with every 11 samples. DNA extraction quality was monitored 
on every 11th sample using a Nanodrop (Thermo Fisher Scientific, Waltham, MA). Samples were tested 
for presence of HCMV, HHV-6A, HHV-6B and HHV-7 using three different quantitative Real Time Taqman 
PCR assays as described [7, 36, 37]. Oligonucleotide sequences and thermocycling conditions were as 
indicated (Table 1). Real Time PCR was undertaken on a Rotor-Gene™ 6000 (Qiagen, Hilden, Germany). 
The fidelity of the PCR enzyme and purity of the DNA-extraction was controlled through amplification of 
the house‐keeping gene, β‐Actin, from every 11th sample. Positive (commercially produced standards), 
negative (molecular grade water), reagent (no template) and extraction controls were included with each 
run. HCMV genomic DNA was purchased from the National Institute for Biological Standards and Control 
(NIBSC, Potters Bar, U.K). Genomic DNA for HHV-6A, HHV-6B and HHV-7 were donated from the reagent 
repository of the HHV-6 Foundation (Santa Barbara, CA, U.S). Standard curves for quantitation of 
betaherpesvirus viral loads were prepared as follows: HCMV: lyophilized standard was re-suspended in 
elution buffer according to manufacturer’s instructions to create a stock solution of 5x106 copies/ml. HHV-
6A, HHV-6B and HHV-7 standards were human sera containing 5x106 copies/ml. 200μls was extracted and 
reconstituted in 200μl elution buffer. For all four viruses 10-fold serial dilutions were made down to 5x10-
1 copies/ml. 5μl of each dilution (25,000, 2500, 250, 25 and 2.5 absolute copies) were then amplified in 
triplicate. The manufacturer’s software was then used to generate standard curves against which Ct values 
of clinical specimens were converted to ‘copies/μl extracted DNA’. Extracted DNA from clinical specimens 
was quantified (ng/μl) using a Nanodrop (Thermo Scientific, Waltham, MA, U.S) and ‘viral genome 
equivalents/μg extracted DNA’ calculated. 
Statistical Analysis 
Data analysis was undertaken using SPSS version 21 (IBM, Armonk, NY, USA). Binary and continuous 
variables were compared by Pearson chi-squared test and Mann Whitney U respectively, between study 
groups and the general admitted population (Table 2). For under- or over-represented covariates, 
weighting variables were calculated using the formula ‘prevalence in hospital population/prevalence in 
sample’ and then multiplied together and divided by the mean weight to make a composite weighting 
variable. This composite weight was then used to estimate hospital population-weighted prevalences for 
each of the betaherpesviruses. Multivariate binary logistic regression analysis (on non-weighted data) was 
used to evaluate possible associations between various clinical and demographic factors and 
betaherpesvirus infection and virus loads. The Wald-Wolfowitz Runs test was used to evaluate the 
randomness of the distribution of positive samples. Median viral loads were compared by HIV status and 
underweight status using the Mann Whitney U test. 
RESULTS 
Patient Recruitment 
We screened DNA-extracted sera from 303 infants aged between 3 weeks and 2 years of age. 42.5% of 
the infants were female, median age was 12 months (IQR 7-17), 34.8% of infants were HIV-infected and 
36.3% of infants were considered to be malnourished on admission (Admitted to the malnutrition ward 
due to weight-for-height z-score < -2 or on clinical grounds at the discretion of the attending physician). 
Comparison with this routine admissions data showed that whilst gender was representative, the study 
infants were significantly older, more likely to be HIV infected and more likely to be malnourished (Table 
2), consistent with suspicion of TB or TB risk factors (HIV infection, household contact etc..), which were 
key inclusion criteria on the parent trial [35]. 
Prevalence of betaherpesvirus infections 
Betaherpesvirus DNAemia was detected by PCR in sera from 59.1% (179/303) of infants (Table 3). All 
negative controls were negative and positive specimens were randomly distributed (analysis not shown). 
HCMV was the most prevalent virus (41.3%, 125/303), significantly more prevalent that HHV-6B (20.5%, 
62/303)(p<0.001) and HHV-7 (20.1% (61/303)(p<0.001). Weighting for the over-representation of HIV 
infected children, older median age and increased prevalence of malnutrition, did not significantly effect 
betaherpesvirus prevalence (Table 3). HHV-6A was rare, with just one case: a male baby of 9 months of 
age, admitted with suspected pneumonia, TB or pertussis. A gastric aspirate was culture negative for TB, 
the baby was HIV negative and had a weight-for-age z-score of -1.22. The mother reported recent loss of 
appetite and weight loss, fevers, productive cough, difficulties breathing, and lethargy. This baby was also 
positive for HCMV and HHV-7, one of just 9 babies positive for 3 betaherpesviruses. 52 cases were co-
infected with two viruses (Table 3). 
Risk factors for betaherpesvirus infections 
HCMV DNAemia was significantly more prevalent among HIV-infected infants, than among HIV-uninfected 
infants (54.5% (55/101) vs 34.0% (65/191), p = 0.001, a univariate effect not seen for HHV-6B or HHV-7 
(Table 3). Multivariate binary logistic regression analysis demonstrated that HCMV DNAemia in infants 
was independently associated with HIV infection (OR 2.31, 95%CI: 1.37-3.90, p = 0.002) and being 
underweight (OR 1.82, 95%CI: 1.06-3.12, p = 0.03)(Table 4). Among 8 children admitted with suspected 
meningitis, 6 were positive for HCMV DNAemia (OR5.72 [1.07-30.5], p=0.041). In our study group 
betaherpesvirus DNAemia was not associated with fever (>=38oC), breast-feeding (an established route 
of transmission for HCMV, although only 13 infants were not being, or had not been, breast fed) or 
reported recent rash (none of the infants presented with a rash)(Table 4).  
The odds of HCMV DNAemia decreased significantly with age (OR 0.95 95%CI: 0.91-0.99, p = 0.008), with 
a similar trend for HHV-6B. Conversely, there was a trend for increased odds of HHV-7 DNAemia with age. 
To investigate these age trends in more detail, we plotted betaherpesvirus DNAemia prevalence by age 
in months (Figure 1a). We observed peaks of HCMV prevalence at 3-5 months, and 18-20 months, 
indicative of early primary infection (with some residual DNAemia from congenital infections) followed by 
reactivation/re-infection in older infants. A higher prevalence of HCMV DNAemia was associated with HIV 
infection (Figure 1b) and being underweight (Figure 1c) across all age groups.  
HHV-6B displayed a similar temporal profile to HCMV, with peaks suggestive of primary and secondary 
infections (figure 1a). The temporal signature of HHV-7 DNAemia was clearly distinct from HCMV and 
HHV-6B, dropping from 20% to 10% over the first 6 months of life, but then steadily increasing back to 
20% by 12 months, and remaining stable (Figure 1a). Co-infections with more than one betaherpesvirus 
were common, detected in 33.5% (60/179) of all cases (51 cases with two viruses, and 9 cases with 3 
viruses) but HIV infected children were no more likely to have a double or triple infection than HIV 
uninfected children (data not shown). There was a significant correlation between HCMV and HHV-6B 
(Pearson correlation 0.157, p =0.006), with HHV-6B DNAemia being associated with increased odds of 
HCMV DNAemia, controlled for HIV status, age and WFAZ score (OR 2.20 [95%CI1.36-4.62], p = 
0.003)(Data not shown). 
Viral Loads 
Comparing viral loads, as defined by ‘betaherpesvirus genome equivalents per microgram of extracted 
DNA’, we found the highest viral loads for HHV-7 (Median:13218, IQR:5185-25195) followed by HCMV 
(Median:2993, IQR:991-10630). HHV-6B median viral load was over a log lower than of HCMV (Median:91, 
IQR:42-192)(Table 5 and Figure 2a). The single HHV-6A positive sample had a relatively high viral load of 
15400 genome equivalents per μg extracted DNA. Stratifying by HIV status, median viral load for HCMV 
was significantly higher among HIV-infected children (Figure 2b)(HIV-uninfected: Median 1985 
(95%CI884-6510) vs HIV-infected: Median 3639 (95%CI 1567-18980)(p = 0.024). Conversely, median 
HCMV viral load did not differ significantly by weight-for-age z–score (data not shown)(p = 0.120). 
Discussion 
Betaherpesvirus DNAemia was detected in two thirds of admitted Zambian infants with HCMV DNAemia 
(41.3%, 125/303) being roughly twice as prevalent as both HHV-6B (20.5%, 62/303) and HHV-7 (20.1%, 
61/303). HCMV DNAemia was twice as prevalent among HIV-infected children consistent with previous 
studies [4], which have also shown links with AIDS progression [38] and death [14]. The persistent 
association of HCMV infection with HIV infection and being underweight is consistent with a previous 
population-based study, which showed that early infant HCMV infection is independently linked with 
impaired physical development of Zambian children [5]. 
The median HCMV viral load (3.9 log10 copies/ml whole blood) was similar to a previous study of 
hospitalized Zambian children [4]. A recent South African study of HCMV pneumonia in infants used ROC 
analysis to determine that a viral load of 4.1 log10 copies/ml whole blood could isolate 70% of cases with 
a positive urine culture [8]. Here we also analyzed ‘copies/μg extracted DNA’ (normalizing for the amount 
of cell DNA present in the specimen) and found that whilst the range of viral loads was extremely broad, 
median HCMV viral load (copies/μg extracted DNA) was significantly higher (by 1 log) among HIV infected 
children, an effect not evident for HHV-6 or HHV-7.  
HCMV is an established co-factor linked with AIDS progression and neurological sequelae [38] and so the 
association of HCMV infection with an admission diagnosis of meningitis is interesting and raises the 
question of to what degree HCMV is causing meningitis in African children, compared with bacterial 
pathogens, and whether it should be diagnosed and treated? A previous study also found that among HIV-
exposed children (those who remain HIV negative but who have HIV positive mothers), HCMV was linked 
with impaired psychomotor development [5]. Other reports from sub-Saharan Africa have identified both 
HCMV and HHV-6 among other viral infections as important causes of hospitalization and mortality among 
children with non-malarial CNS infections [30, 39]. Studies have shown that detection of HCMV DNA in 
the CSF of patients with suspected meningitis is associated with mortality in both adults [40, 41] and 
children [42].  
With respect to HHV-6B our findings are consistent with a large study from the U.S that demonstrated 
active HHV-6 infection in 20% of infants admitted with febrile illness [22]. Previous studies from Zambia 
with smaller sample sizes have detected HHV-6 DNA in the whole blood of 5-30% of children admitted 
with febrile illness [3, 43]. Classical sequencing over a hypervariable region within the U47 locus identified 
HHV-6A in 37.5-57% of those that were successfully sequenced [3, 43]. This indication that HHV-6A might 
be a prevalent infant infection in Africa was followed up by a population-based study of healthy children, 
which identified HHV-6A in 99% (55/56)(of which 7 cases were co-infected with HHV-6B) and HHV-6B in 
15% (8/56) of positives [3]. In light of these previous findings we were surprised to find such a low 
prevalence of HHV-6A. We detected HHV-6A and HHV-6B using a highly sensitive and specific multiplex 
Taqman-based Real Time PCR assay with conserved primers but species-specific probes targeting the 
HHV-6 DNA polymerase gene (U38) [7]. In co-infected patients, the use of conserved primers may result 
in the masking of the species with lower copy number, but this alone is unlikely to explain the stark 
contrast between the two studies. There is some limited evidence within the U47 gene for isolates 
containing both HHV-6A and HHV-6B elements [3, 44], although globally, complete genomic sequences 
for HHV-6 have only been published for four strains: [45-52]. HHV-6 is integrated into the telomeric 
repeats of roughly 1% of European and 0.2% of Japanese populations, typically characterized by high loads 
of HHV-6 DNA in clinical samples [53]. None of the HHV-6-positive samples on this study displayed viral 
loads (5 log/μg DNA) that might be consistent with chromosomal integration [54]. 
The distribution of betaherpesvirus prevalence by age, showed profiles indicative of early primary 
infection with HCMV and HHV-6B peaking between 3-6 months of age, followed by secondary infection 
or re-activation in children older than 12 months of age. For HCMV this is consistent with previous African 
studies [5] but different from high-income populations where HCMV infection is later [55]. For HHV-6B 
our data is consistent with a U.S study [22]. The distribution of HHV-7 infections was distinct from HCMV 
and HHV-6B, with most primary infections appearing to occur in young neonates, followed by a steady 
increase in probable reactivated infections during the first year of life, and a very stable prevalence of 
around 20% among admitted children older than 12 months of age. We present the first data on HHV-7 
infections in African infants and the age distribution is consistent with serological data from Brazil [56], 
yet contrary to U.S data which suggests primary infection with HHV-7 peaks later than HHV-6B [57]. 
There were several limitations to this study: Analysis of a single sera prevents detailed determination of 
the clinical and virological course of individual betaherpesvirus infections. The diagnostic tests used 
cannot accurately differentiate between active infections causal of pathology, and sub-clinical DNAemia 
arising from reactivated infections secondary to other infections and diseases. Similarly, in the absence of 
serological data we cannot confirm whether individual infections were primary or secondary, although we 
could infer some indication of the presence of primary and secondary infections from the age distribution. 
The use of commercial assays would have greatly strengthened comparisons of prevalence and viral loads 
with other studies. We did not have access to maternal HIV status preventing comparison of the relevance 
of HCMV infections in HIV-exposed children, seen in previous studies [5], and could not determine how 
many of the infections were acquired in utero We did not have infant height data and so could not 
calculate z-scores for stunting and wasting, which are more accurate markers of growth delay than 
underweight (weight-for-age z-score).  
Despite these limitations, our findings add weight to previous studies which demonstrate that HCMV 
infections (both congenital [15, 16, 19] and infant infections [5, 8, 14, 28, 29]) are emerging as important 
determinants of health and development in African children.  
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HHV-6A – human herpesvirus 6A 
HHV-6B – human herpesvirus 6B 
HHV-7 – human herpesvirus 7 
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CNS – central nervous system 
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PCR – polymerase chain reaction 
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Table 1: Oligonucleotide sequences and thermocycling conditions 
Target Primers and Probes 5’-3’ Cycling Conditions 
HCMV UL83[37] Forward Primer CAGTCCCGAGACMGTGAGAC 
Reverse Primer TGAACATCCCCAGCATCAACG 
Probe: FAMb-TGCCACATCTGCTTGCCCGACGC-BBQb 
Hold @ 95°c, 10 min 
Cycling (45 repeats) 
Step 1 @ 95°c, hold 10 secs 
Step 2 @ 58°c, hold 20 secs 
Step 3 @ 72°c, hold 1 secs 
HHV-6A and HHV-6B[7] Forward primer GGAGTGCCTGTGGGTATTC  
Reverse primer CTAAGGTGAGCCAGATTCG  
HHV6A Probe: HEX-TGCAGCCATTTCTTTGGAAAGC-TAMRA  
HHV6B probe: FAM-TGCAGCCACCTCCTTGGAAAG-TAMRA  
Hold @ 94°c, 5 min 
Cycling (55 repeats) 
Step 1 @ 94°c, hold 15 secs 
Step 2 @ 60°c, hold 60 secs 
HHV-7[36] Forward Primer  TTTCCTGTGACAAAAGAAGCAGTTA 
Reverse Primer ATCCCACACGCTTTACGGG 
Probe: FAM-TTCCTGCGCAATAAAGTGAAAACTGTTAGCATT-TAMRA 
Hold @ 50°c, 2 min 
Cycling (60 repeats) 
Step 1 @ 95°c, hold 20 secs 
Step 2 @ 60°c, hold 60 secs 
β-actin Forward Primer: CACACTGTGCCCATCTACGA  
Reverse Primer: CTCAGTGAGGATCTTCATGAGGTAGT 
Probe: FAM-ATGCCCTCCCCCATGCCATCCTGCGT-TAMRA 
Hold 94oC 3 min 
Cycling (45 cycles) 
Step 1 @ 94oC 
Step 2 @ 65oC hold 50 secs 
 
Table 2: Comaprison of key descriptive variables between the study group and admitted population 
 Study Group Admitted population 
n = 303 1176 
Dates Jun 2011 – Apr 2012 Apr-May 2011 
Female Gender 128/301 (42.5%) 532/1167 (44.8%) 
Median Age (IQR) 12 (7-17) months a 8 (3-13) months a 
Infant HIV infection 101/290 (34.8%) b 147/1142 (12.9%) b 
Mortality ND 128/1171 (10.9%) 
Malnutrition noted on admission 110/303 (36.3%) c 117/1176 (9.9%)c 
Where denominators differ from total sample size this represents missing data for that variable. 
Significance was by Pearson chi-squared for binomial variables, by Mann Whitney U test for age and student t test 
for birth weight. 
a, b,c p < 0.001, ND = No Data  
 
Table 3: Betaherpesvirus prevalence stratified by HIV status 
 Unweighted (%. SE) Weighteda (%, SE) HIV uninfected
b 
(%, SE) 
HIV infectedb 
(%, SE) 
p 
Any betaherpesvirus 179/303 (59.1, 2.8) 170/303 (56.0, 2.9) 105/191 (55, 3.6) 68/101 (67.3, 4.7) 0.041 
Totals      
   HCMV  125/303 (41.3, 2.8)c,d 111/303 (36.5, 2.8) 65/191 (34, 3.4) 55/101 (54.5, 5.0) 0.001 
   HHV-6A 1/303 (0.3, 0.3) 2/303 (0.6, 0.4) 1/191 (0.5, 0.5) 0/101 (0%) 0.466 
   HHV-6B 62/303 (20.5, 2.3)c 73/303 (24.0, 2.5) 44/191 (23, 3.1) 17/101 (16.8, 3.7) 0.215 
   HHV-7 61/303 (20.1, 2.3)d 53/303 (17.4, 2.2) 42/191 (22, 3.0) 17/101 (16.8, 3.7) 0.296 
Co-infections      
   HCMV + HHV-6B 27/303 (8.9, 1.6) 33/303 (10.8, 1.8) 18/191 (9.4, 2.1) 8/101 (7.9, 2.7) 0.668 
   HCMV + HHV-7 16/303 (5.3, 1.3) 9/303 (2.9, 1.0) 11/191 (5.8, 1.7) 5/101 (5.0, 2.2) 0.773 
   HHV-6B + HHV-7 9/303 (3, 0.9) 7/303 (2.4, 0.9) 7/191 (3.7, 1.4) 2/101 (2.0, 1.4) 0.428 
   HCMV + HHV-6B + 
HHV-7 8/303 (2.6, 0.9) 8/303 (2.4, 0.9) 5/191 (2.6, 1.2) 3/101 (3.0, 1.7) 0.861 
   HCMV + HHV-6A + 
HHV-7 1/303 (0.3, 0.3) 2/303 (0.6, 0.5) 1/191 (0.5, 0.5) 0/101 (0, 0) 0.466 
a Weighted for recruitment biases in age, infant HIV status and malnutrition status on admission 
b Unweighted data stratified by HIV status 
c,d p < 0.001 
Significance is by Pearson chi squared 
Table 4: Multivariate binary logistic regression analysis of risk factors associated with betaherpesvirus 
DNAaemia in pediatric admissions <2yrs of age 
 HCMV 
(>200 copies/ml sera) 
HHV-6B  
(>200 copies/ml sera) 
HHV-7 
 aOR [95% CI] p = aOR [95% CI] p = aOR [95% CI] p = 
Male gender 1.12 [0.68-1.85] 0.654 0.59 [0.34-1.06] 0.076 0.69 [0.38-1.27] 0.689 
HIV Infected 2.31 [1.37-3.90] 0.002 0.74 [0.39-1.41] 0.361 0.60 [0.31-1.15] 0.125 
Fever (>= 38oC) 1.01 [0.47-2.19] 0.976 0.54 [018-1.63] 0.277 1.02 [0.41-2.53] 0.963 
Underweight (WFAZ < -2) 1.82 [1.06-3.12] 0.030 0.92 [0.50-1.71] 0.791 1.01 [0.55-1.88] 0.967 
Age (months) 0.95 [0.91-0.99] 0.012 0.96 [0.92-1.01] 0.080 1.04 [1.0 -1.09] 0.064 
Breast Fed 2.53 [0.72-8.87] 0.147 3.59 [0.45-28.9] 0.230 2.39 [0.30-19.2] 0.414 
Rash in the past month 2.27 [0.77-6.68] 0.136 1.56 [0.44-5.57] 0.495 0.61 [0.22-1.70] 0.345 
Admissions Diagnosis       
Pneumonia 0.74 [0.45-1.24] 0.251 0.97 [0.53-1.76] 0.913 1.39 [0.76-2.53] 0.281 
Acute Diarrhoea + 
Dehydration 
1.17 [0.53-2.60] 0.701 0.73 [0.26-2.03] 0.549 1.73 [0.71-4.19] 0.846 
Malaria 0.66 [0.17-2.58] 0.546 1.34 [0.34-5.32] 0.675 0.35 [0.40-2.81] 0.323 
Meningitisa 5.72 [1.07-30.5] 0.041 0.40 [0.50-3.36] 0.396 NC NC 
aOf 8 children admitted with suspected meningitis, 6 were positive for HCMV, 1 was positive for HHV-6B and none 
were positive for HHV-7 
aOR = adjusted odds ratio. Analysis of all three viruses was adjusted for the effects of age, infant HIV status and 
being underweight, as defined by having a weight-for-age z-score (WFAZ) < -2. 
NC = not calculable 
NB. Odds of betaherpesvirus infections were unaffected by infant TB status 
 
 
Table 5: Betaherpesvirus loads 
 
 Genome equivalents/μg extracted DNA Genome equivalents/ml whole blood 
 Median IQR Min Max Median IQR Min Max 
HCMV 2993a,b 991-10630 31 207262671 9404 3739-38640 207 775162391 
HHV-6A 15400 15400-15400 15400 15400 172812 172812-172812 172812 172812 
HHV-6B 91a,c 42-192 2 27389 498 296-1062 201 27115 
HHV-7 13218b,c 5185-25195 247 5267277 56868 23772-140704 4005 9547567 
a,b,c p < 0.001 Mann Whitney U 
 
Figure 1a: Betaherpesvirus prevalence stratified by age among admitted neonates <2 years of age 
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Figure 1b: HCMV prevalence stratified by age and HIV status among admitted infants 
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Figure 1c: HCMV prevalence stratified by age and underweight among admitted infants 
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Figure 2A: Betaherpesvirus genomes copies/μg extracted DNA 
 
Boxes indicate interquartile range, whiskers indicate 5th and 95th percentiles. Circles represent outliers. 
 
Figure 2B: Betaherpesvirus genome copies stratified by HIV status 
 
 
Boxes indicate interquartile range, whiskers indicate 5th and 95th percentiles. Circles represent outliers. 
 
 
 
 
 
 
 
 
 
 
 
